Taken together, our data provide an evidence that LCZ696 has therapeutic potential to restrict DN progression by inhibiting oxidative stress, NF-kB mediated inflammation and glomerulosclerosis. The gene discussed is NFKB1; the disease is glomerulosclerosis.